Product Reports Resources Pricing Login Book a demo

NeuroPace

Health Tech & Medtech · Mountain View, United States · Founded 1999 · IPO 2021

Developing and marketing implantable devices for the treatment of neurological disorders MoreLess

NeuroPace is a medical device company that has developed a brain-responsive neuromodulation system for treating epilepsy. This system, known as the RNS System, is designed to monitor and respond to a patient's brain activity to prevent seizures. The company's primary market is individuals with refractory epilepsy, a form of the condition that does not respond to medication.

The RNS System is an implantable device that provides personalized treatment by delivering electrical stimulation to the brain when it detects abnormal activity. This approach is intended to reduce the frequency and severity of seizures, improving the quality of life for patients. The company operates on a business model that involves the sale of these devices to healthcare facilities and providing ongoing support and data analysis services.

NeuroPace is a publicly traded company, and its revenue is generated through the sale of the RNS System and related components. The company is focused on expanding the adoption of its technology and continuing to develop its platform for other neurological disorders.

Keywords: medical devices, neuromodulation, epilepsy treatment, implantable devices, neurostimulation, brain-computer interface, personalized medicine, seizure prevention, refractory epilepsy, neurological disorders

Valuation $456M
Revenue $100M
Total funding $100–500M

Talent graph

NeuroPace's talent

Book a demo to see the people
Employees mapped 245 incl. 4 AI specialists
Founders Hidden — book a demo/100 quality score
Key operators 10 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

16 investors on NeuroPace's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 1 investor entered at this stage
Series B+ 15 investors entered at this stage
Technology Partners
Domain Associates
Medventure
NEA
InterWest Partners
Johnson & Johnson
MedVenture Associates
Johnson & Johnson Development Corporation
OrbiMed
KCK
Armentum Partners
Soleus Capital
Accelmed
Revelation Partners
Midcap Financial

Global footprint

Where NeuroPace has talent and traffic

Workforce by country
2 countries with
team presence
🇺🇸 United States99.4%
🇧🇷 Brazil0.6%
2 countries shown
Web traffic by country
17K monthly visits
across markets
🇺🇸 United States66.5%
🇨🇦 Canada13.5%
🇬🇧 United Kingdom8.8%
🇮🇳 India5.9%
🇦🇺 Australia3.5%
Top 5 markets shown

Market sentiment

What the market is saying about NeuroPace

An AI-synthesized read of the highest-engagement posts about NeuroPace on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See NeuroPace on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.